Cardiol Therapeutics Inc. - Class A Common Shares (CRDL)
1.4100
+0.0100 (0.71%)
Cardiol Therapeutics is a biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases
The company is dedicated to advancing the treatment of heart conditions by leveraging its proprietary formulations and research into the therapeutic potential of cannabidiol, a compound derived from cannabis. Through rigorous scientific investigation and clinical trials, Cardiol aims to produce effective solutions that can improve quality of life for patients suffering from various heart-related ailments, with a vision of making significant contributions to the field of cardiology.
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.
During Friday's session, 198 companies made new 52-week lows.
Key Facts About Today's 52-Week Highs And Lows:
Alibaba Group Holding (NYSEBABA) is the largest...
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies.
On Tuesday, Cardiol Therapeutics Inc. (NASDAQCRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in Cardiol's novel CRD-38 subcutaneous (SUBQ) formulati
Gainers Near Intelligence, Inc. (NASDAQNIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.
Gainers Bright Green Corp. (NASDAQBGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange.
The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) from Cardiol Therapeutics Inc. (NASDAQCRDL) to start a Phase 2 open-label pilot study designed to evaluate the tolerance and safety of CardiolRx, in patients with recurrent pericarditis.
Gainers
Casa Systems, Inc. (NASDAQCASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...
Gainers
Casa Systems, Inc. (NASDAQCASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions....
Gainers
MedAvail Holdings, Inc. (NASDAQMDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...
Upgrades
Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQAZPN) from Hold to Buy. In the second quarter, Aspen Technology showed an EPS of $1.20,...
